• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Chief Operating Officer Hollenshead Stuart

    2/21/25 5:15:08 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRPH alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Hollenshead Stuart

    (Last) (First) (Middle)
    711 STEWART AVENUE,
    SUITE 200

    (Street)
    GARDEN CITY, NY 11530

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ProPhase Labs, Inc. [ PRPH ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Operating Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    02/17/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Option (right to buy)(1) $0.6 02/17/2025 A 500,000 (1) 02/17/2032 Common Stock 500,000 $0 500,000 D
    Explanation of Responses:
    1. Stock option granted as an inducement award. The option vests over a three-year period, with 25% vesting on the date of grant and 25% vesting on each of the next three anniversaries thereafter, subject to the Reporting Person's continued service through each vesting date.
    /s/ Stuart Hollenshead 02/21/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PRPH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRPH

    DatePrice TargetRatingAnalyst
    1/14/2022$12.00 → $15.00Buy
    HC Wainwright & Co.
    12/20/2021$12.00Buy
    HC Wainwright & Co.
    10/13/2021Buy → Neutral
    Dawson James
    More analyst ratings

    $PRPH
    SEC Filings

    View All

    SEC Form 10-Q filed by ProPhase Labs Inc.

    10-Q - ProPhase Labs, Inc. (0000868278) (Filer)

    11/19/25 4:06:08 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProPhase Labs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ProPhase Labs, Inc. (0000868278) (Filer)

    11/19/25 9:00:52 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-Q filed by ProPhase Labs Inc.

    NT 10-Q - ProPhase Labs, Inc. (0000868278) (Filer)

    11/14/25 4:15:04 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Abenante Carolina

    3 - ProPhase Labs, Inc. (0000868278) (Issuer)

    11/10/25 9:55:56 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CEO & CHAIRMAN Karkus Ted William

    4 - ProPhase Labs, Inc. (0000868278) (Issuer)

    9/11/25 4:05:22 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Operating Officer Hollenshead Stuart

    4 - ProPhase Labs, Inc. (0000868278) (Issuer)

    2/21/25 5:15:08 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ProPhase Labs Reported Results for the Third Quarter Ended September 30, 2025, and Will Hold a Virtual Conference Call Today at 2pm ET.

    ProPhase Labs in discussions for strategic initiative to realize significant underlying value in the Company. Voting for Current Proxy Critically Important. Crown Medical Achieves Final Hurdle. Appointed Special Counsel to Launch Litigation Against Insurance Companies. First Settlement Completed. Reiterates $50 MILLION Net A/R Goal Next-Phase Commercialization of BE-Smart™ Underway Following Landmark Study Published in the Official Journal of the American College of Gastroenterology UNIONDALE, NY, Nov. 19, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) (the "Company" or "ProPhase") today announced it is in M&A related discussions not connected to a crypto treasury strategy.

    11/19/25 8:13:06 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProPhase Labs, Inc. to Present Third Quarter 2025 Financial Results on November 19

    UNIONDALE, NY, Nov. 18, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH) (the "Company" or "ProPhase"), a next generation biotech, genomics and consumer products company, announced today that they will be presenting third quarter 2025 financial results on a virtual conference call hosted by Renmark Financial on November 19, 2025, at 2:00 pm EST. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors and other individual followers to register and attend this live event. Investors interested in participating in this live event will need to register using the link below. After the event, a rep

    11/18/25 8:00:00 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProPhase Labs Urges Shareholders to Vote by November 23 on Proxy Proposals

    UNIONDALE, NY, Nov. 17, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) reminds shareholders of record as of October 20, 2025, of the Company's upcoming Special Meeting of Stockholders, which will be held on November 24, 2025, at 10:00 a.m. ET. Shareholders of record as of October 20, 2025, will be able to attend the Special Meeting in person at 273 Merrick Road, Lynbrook, NY 11563. Shareholders are advised to vote their shares well in advance of the proxy voting deadline of 11:59 p.m. ET, on November 23, 2025. The proposals are included in the definitive proxy statement filed with the U.S. Securities and Exchange Commission. The proxy statement is available at: https://www.sec

    11/17/25 8:00:00 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on ProPhase Labs with a new price target

    HC Wainwright & Co. reiterated coverage of ProPhase Labs with a rating of Buy and set a new price target of $15.00 from $12.00 previously

    1/14/22 6:36:15 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. initiated coverage on ProPhase Labs with a new price target

    HC Wainwright & Co. initiated coverage of ProPhase Labs with a rating of Buy and set a new price target of $12.00

    12/20/21 6:25:15 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProPhase downgraded by Dawson James

    Dawson James downgraded ProPhase from Buy to Neutral

    10/13/21 10:48:44 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRPH
    Leadership Updates

    Live Leadership Updates

    View All

    Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 18, 2025 /PRNewswire/ -- USA News Group News Commentary – According to a recent report in Newsweek, more Americans younger than 50 are getting cancer. In fact, the report cites a recent study from the National Institutes of Health (NIH), which found that between 2010 and 2019, more than 2 million Americans aged 15 to 49 were diagnosed with cancer, with early-onset cases rising significantly in 14 different cancer types, including breast, colorectal, and kidney cancers. The dire statistics from the study come at a time where Bloomberg has recently reported on the skyrocketing costs of cancer drugs,

    6/18/25 11:19:00 AM ET
    $CATX
    $CGON
    $GALT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Pharmaceutical Preparations

    ProPhase Labs hires Stuart Hollenshead as COO, the former COO and CBO of Barstool Sports

    GARDEN CITY, NY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and consumer products company, today announced the appointment of Stu Hollenshead as Chief Operating Officer, marking a pivotal step in the company's expansion into consumer-centered health and wellness products. As COO, Hollenshead will focus on accelerating ProPhase Labs' consumer-facing strategy, leveraging his deep expertise in direct-to-consumer growth, subscription models, digital marketing, and audience monetization to position the company as a leader in science-backed health solutions. The Company plans to provide additional updat

    2/18/25 8:00:00 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProPhase Labs Unveils Project ZenQ-AI

    Leveraging ProPhase Labs' AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development. Garden City, NY, April 16, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a biopharma, genomics, and diagnostics Company, today announced an innovative step forward in cancer treatment research with the introduction of Project ZenQ-AI. This project employs the Company's state-of-the-art AI platform which was meticulously developed with leading AI technology platforms and systems. The Company is harnessing its extensive genomic database—built over the last six years from whole genome sequencing tests (W

    4/16/24 8:00:00 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRPH
    Financials

    Live finance-specific insights

    View All

    ProPhase Labs Reported Results for the Third Quarter Ended September 30, 2025, and Will Hold a Virtual Conference Call Today at 2pm ET.

    ProPhase Labs in discussions for strategic initiative to realize significant underlying value in the Company. Voting for Current Proxy Critically Important. Crown Medical Achieves Final Hurdle. Appointed Special Counsel to Launch Litigation Against Insurance Companies. First Settlement Completed. Reiterates $50 MILLION Net A/R Goal Next-Phase Commercialization of BE-Smart™ Underway Following Landmark Study Published in the Official Journal of the American College of Gastroenterology UNIONDALE, NY, Nov. 19, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) (the "Company" or "ProPhase") today announced it is in M&A related discussions not connected to a crypto treasury strategy.

    11/19/25 8:13:06 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProPhase Labs, Inc. to Present Third Quarter 2025 Financial Results on November 19

    UNIONDALE, NY, Nov. 18, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ:PRPH) (the "Company" or "ProPhase"), a next generation biotech, genomics and consumer products company, announced today that they will be presenting third quarter 2025 financial results on a virtual conference call hosted by Renmark Financial on November 19, 2025, at 2:00 pm EST. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors and other individual followers to register and attend this live event. Investors interested in participating in this live event will need to register using the link below. After the event, a rep

    11/18/25 8:00:00 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProPhase Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025

    ProPhase Delivers Significant Operational and Financial Improvements, Advances Multiple Non-Dilutive Liquidity Initiatives, and Targets Transformational Growth Catalysts Company granted key U.S. patent on BE-Smart™ Esophageal Adenocarcinoma Risk Assessment test (August 2025) Company to hold a virtual conference call Wednesday, August 13, 2025, at 2:00 PM ET UNIONDALE, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH), (the "Company" or "ProPhase") a diversified diagnostics, genomics, and consumer healthcare company, today reported financial and operational results for the three and six months ended June 30, 2025. Ted Karkus, CEO of ProPhase Labs, will present to s

    8/13/25 8:00:00 AM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by ProPhase Labs Inc. (Amendment)

    SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)

    3/19/24 4:18:00 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by ProPhase Labs Inc. (Amendment)

    SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)

    4/5/23 4:37:55 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by ProPhase Labs Inc. (Amendment)

    SC 13D/A - ProPhase Labs, Inc. (0000868278) (Subject)

    4/4/23 4:25:33 PM ET
    $PRPH
    Biotechnology: Pharmaceutical Preparations
    Health Care